Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti PD-1”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT04641871
What this trial is testing

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

Who this might be right for
Metastatic CancerSolid Tumor
Symphogen A/S 78
Testing effectiveness (Phase 2)Study completedNCT05578872
What this trial is testing

ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

Who this might be right for
Melanoma (Skin)Cutaneous MelanomaAdult Disease+2 more
Anaveon AG 29
Early research (Phase 1)Looking for participantsNCT05659628
What this trial is testing

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

Who this might be right for
Diffuse Large B-cell Lymphoma
Ningbo No. 1 Hospital 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT05081609
What this trial is testing

Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Who this might be right for
Advanced Solid TumorLocally Advanced Solid TumorMetastatic Solid Tumor+10 more
Ascendis Pharma Oncology Division A/S 320
Testing effectiveness (Phase 2)Study completedNCT04570332
What this trial is testing

BO-112 With Pembrolizumab in Unresectable Malignant Melanoma

Who this might be right for
Melanoma
Highlight Therapeutics 42
Early research (Phase 1)Study completedNCT03311412
What this trial is testing

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Who this might be right for
Metastatic CancerSolid TumorLymphoma
Symphogen A/S 89
Not applicableStudy completedNCT06586580
What this trial is testing

Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1

Who this might be right for
Metastatic Melanoma
Centre Hospitalier Universitaire de Besancon 18
Testing effectiveness (Phase 2)WithdrawnNCT04373083
What this trial is testing

Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Regeneron Pharmaceuticals
Testing effectiveness (Phase 2)UnknownNCT05055583
What this trial is testing

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

Who this might be right for
NSCLC Stage IVOligometastasis
Tang-Du Hospital 30
Testing effectiveness (Phase 2)Study completedNCT04988841
What this trial is testing

Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma

Who this might be right for
Melanoma
Assistance Publique - Hôpitaux de Paris 70
Testing effectiveness (Phase 2)Ended earlyNCT03173950
What this trial is testing

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Who this might be right for
MedulloblastomaEpendymomaPineal Region Tumors+2 more
National Cancer Institute (NCI) 136
Testing effectiveness (Phase 2)UnknownNCT05512520
What this trial is testing

Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）

Who this might be right for
Metastatic Esophageal Squamous Cell Carcinoma
Sun Yat-sen University 126
Not applicableStudy completedNCT03305380
What this trial is testing

Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth

Who this might be right for
Stage IV Non-small Cell Lung Cancer
Maastricht Radiation Oncology 637
Testing effectiveness (Phase 2)UnknownNCT03925090
What this trial is testing

Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

Who this might be right for
Nasopharyngeal Carcinoma
Sun Yat-sen University 150
Early research (Phase 1)Active Not RecruitingNCT05007782
What this trial is testing

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Gilead Sciences 304
Testing effectiveness (Phase 2)Looking for participantsNCT03591276
What this trial is testing

Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Shaare Zedek Medical Center 15
Early research (Phase 1)Study completedNCT03203876
What this trial is testing

A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

Who this might be right for
Advanced Cancer
Bristol-Myers Squibb 10
Early research (Phase 1)Temporarily pausedNCT07395258
What this trial is testing

Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Who this might be right for
Solid Tumors
Boehringer Ingelheim 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT03607890
What this trial is testing

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Who this might be right for
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 TherapyMSI-H Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT03680508
What this trial is testing

TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

Who this might be right for
Adult Primary Liver CancerAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver Cancer
University of Hawaii 42
Next Page